Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.
August, 2022
|
November 11, 2021
|
January 18, 2023
Sidoti Small-Cap Virtual Investor Conference
|
September 12 2022
H.C. Wainwright 24th Annual Global Investment Conference
|
June 10 2022
Jefferies Healthcare Conference
|
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET. A webcast of the...
Presented New Preclinical Data at Recent Medical Meetings ShowingDisease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer andAppointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securitiesas of September 30, 2022 Provides Strong Financial Foundation andExtends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain...
Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek Medical Center GBA-Parkinson’s Disease Symposium BETHESDA, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel...
Contact IR
Company
GAIN THERAPEUTICS INC.
4800 Montgomery Lane Ste
220 Bethesda, MD 20814,
Phone: +1 301 500 1556